A Study to Investigate LYL845 in Adults With Solid Tumors
收藏NIAID Data Ecosystem2026-03-14 收录
官方服务：
资源简介：
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
创建时间：
2022-12-15
